ArticleJournal of clinical medicine2026

Real-World Safety and Circuit Outcomes of Protocolized Divided-Dose Enoxaparin During Continuous Renal Replacement Therapy Without Routine Anti-Xa Monitoring: A Single-Center Competing-Risk Cohort Study.

Hasan Burak Toprak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.